SG11201407812SA - Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives - Google Patents
Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additivesInfo
- Publication number
- SG11201407812SA SG11201407812SA SG11201407812SA SG11201407812SA SG11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- protein
- aggregates
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000006259 organic additive Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000000356 contaminant Substances 0.000 title abstract 2
- 150000007945 N-acyl ureas Chemical class 0.000 abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 abstract 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002873 Polyethylenimine Polymers 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000458 allantoin Drugs 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960003260 chlorhexidine Drugs 0.000 abstract 1
- 238000005352 clarification Methods 0.000 abstract 1
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 abstract 1
- 229960001588 ethacridine Drugs 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 229920000620 organic polymer Polymers 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229940045136 urea Drugs 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/180650 A1 (51) International Patent Classification: C07K1/14( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/SG2013/000049 6 February 2013 (06.02.2013) English English (30) Priority Data: 61/653,752 31 May 2012 (31.05.2012) US (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). (72) Inventor: GAGNON, Peter; 20 Biopolis Way, #06-01 Centres, Singapore 138668 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road, Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) © o 00 i-H en i-H o CJ o & (54) Title: METHODS FOR REDUCING LEVELS OF PROTEIN-CONTAMINANT COMPLEXES AND AGGREGATES IN PROTEIN PREPARATIONS BY TREATMENT WITH ELECTROPOSITIVE ORGANIC ADDITIVES (57) Abstract: Methods for reduction of aggregate levels in antibody and other protein preparations through treatment with low con centrations of electropositive organic additives (e.g., ethacridine, chlorhexidine, or polyethylenimine) in combination with ureides (e.g., urea, uric acid, or allantoin) or organic modulators (e.g., nonionic organic polymers, surfactants, organic solvent or ureides). Some aspects of the invention relate to methods for reducing the level of aggregates in conjunction with clarification of cell culture harvest. It further relates to the integration of these capabilities with other purification methods to achieve the desired level of final purification.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653752P | 2012-05-31 | 2012-05-31 | |
PCT/SG2013/000049 WO2013180650A1 (en) | 2012-05-31 | 2013-02-06 | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407812SA true SG11201407812SA (en) | 2014-12-30 |
Family
ID=49673721
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407812SA SG11201407812SA (en) | 2012-05-31 | 2013-02-06 | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
SG10201606990TA SG10201606990TA (en) | 2012-05-31 | 2013-02-06 | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201606990TA SG10201606990TA (en) | 2012-05-31 | 2013-02-06 | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
Country Status (8)
Country | Link |
---|---|
US (1) | US10246506B2 (en) |
EP (1) | EP2855502B1 (en) |
JP (2) | JP2015519361A (en) |
KR (1) | KR102067445B1 (en) |
CN (1) | CN104507953B (en) |
IN (1) | IN2014DN09948A (en) |
SG (2) | SG11201407812SA (en) |
WO (1) | WO2013180650A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150115745A (en) * | 2013-02-06 | 2015-10-14 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | Methods for reducing aggregate content in protein preparations |
WO2014133458A1 (en) * | 2013-02-26 | 2014-09-04 | Agency For Science, Technology And Research | Protein purification in the presence of nonionic organic polymers and electropositive surfaces |
CN105008384A (en) * | 2013-02-28 | 2015-10-28 | 新加坡科技研究局 | Protein purification in the presence of nonionic organic polymers at elevated conductivity |
CN106061993A (en) * | 2014-02-27 | 2016-10-26 | 新加坡科技研究局 | Methods for reducing aggregate content of protein preparations by treatment with aryl anions |
SG11201607098SA (en) * | 2014-02-27 | 2016-09-29 | Agency Science Tech & Res | Antibody purification process |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
CN109311937A (en) * | 2016-06-15 | 2019-02-05 | 新加坡科技研究局 | Method of the enhancing for the chromatographic performance of protein purification |
JP2019527729A (en) | 2016-07-13 | 2019-10-03 | リフォーム バイオロジクス、エルエルシー | Stabilizing excipients for therapeutic protein formulations |
DE102016010601B4 (en) | 2016-09-01 | 2018-11-08 | Sartorius Stedim Biotech Gmbh | A process for the purification of viruses or virus-like particles using a crosslinked cellulose hydrate membrane |
WO2019036619A1 (en) * | 2017-08-18 | 2019-02-21 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
CN113493570B (en) * | 2020-04-01 | 2022-11-01 | 中国科学院理化技术研究所 | Method for reducing endotoxin in gelatin by adopting allantoin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
AU597924B2 (en) * | 1985-12-11 | 1990-06-14 | Natinco Nv | Solubilization of protein aggregates |
DE69431236T2 (en) * | 1993-10-06 | 2003-01-02 | Amgen Inc | STABLE PROTEIN PHOSPHOLIPID COMPOSITIONS AND METHOD |
US5691132A (en) | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
SE9500778D0 (en) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
SE0201257D0 (en) * | 2002-04-25 | 2002-04-25 | Medical Invest In Sweden Ab | Improved Separation |
CN1286453C (en) * | 2003-07-25 | 2006-11-29 | 复旦大学 | Method for stablizing protein medicine and its application in microball preparation |
AU2008209404B2 (en) | 2007-01-22 | 2012-08-16 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
JP5496898B2 (en) * | 2007-10-12 | 2014-05-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Methods and agents for protein refolding |
CN102119168A (en) * | 2008-06-03 | 2011-07-06 | 帕特里有限公司 | Process for purification of antibodies |
EP2241886A1 (en) * | 2009-04-15 | 2010-10-20 | Beckman Coulter Biomedical Limited | Homogeneous agglutination immunoassay method and kit for such method |
WO2012040216A1 (en) * | 2010-09-20 | 2012-03-29 | Bio-Rad Laboratories, Inc. | Dissociation of product-complexed contaminants in chromatography |
KR102065355B1 (en) * | 2012-05-31 | 2020-01-13 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations |
WO2013180647A1 (en) * | 2012-05-31 | 2013-12-05 | Agency For Science, Technology And Research | Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities |
KR20150023297A (en) * | 2012-05-31 | 2015-03-05 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | Selective binding of biological targets to solid phase ureides |
-
2013
- 2013-02-06 SG SG11201407812SA patent/SG11201407812SA/en unknown
- 2013-02-06 WO PCT/SG2013/000049 patent/WO2013180650A1/en active Application Filing
- 2013-02-06 SG SG10201606990TA patent/SG10201606990TA/en unknown
- 2013-02-06 EP EP13797757.5A patent/EP2855502B1/en active Active
- 2013-02-06 CN CN201380040495.4A patent/CN104507953B/en not_active Expired - Fee Related
- 2013-02-06 KR KR1020147033043A patent/KR102067445B1/en active IP Right Grant
- 2013-02-06 JP JP2015514965A patent/JP2015519361A/en active Pending
-
2014
- 2014-11-24 IN IN9948DEN2014 patent/IN2014DN09948A/en unknown
- 2014-11-26 US US14/555,224 patent/US10246506B2/en not_active Expired - Fee Related
-
2017
- 2017-07-25 JP JP2017143236A patent/JP6491277B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20150028231A (en) | 2015-03-13 |
JP6491277B2 (en) | 2019-03-27 |
CN104507953B (en) | 2018-05-18 |
US20150148526A1 (en) | 2015-05-28 |
IN2014DN09948A (en) | 2015-08-14 |
US10246506B2 (en) | 2019-04-02 |
SG10201606990TA (en) | 2016-10-28 |
EP2855502A4 (en) | 2016-02-17 |
EP2855502B1 (en) | 2019-06-26 |
JP2015519361A (en) | 2015-07-09 |
WO2013180650A1 (en) | 2013-12-05 |
JP2017222699A (en) | 2017-12-21 |
CN104507953A (en) | 2015-04-08 |
EP2855502A1 (en) | 2015-04-08 |
KR102067445B1 (en) | 2020-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407812SA (en) | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
SG11201408174UA (en) | Antibody formulation | |
SG11201407774XA (en) | Conversion of biomass | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201407200TA (en) | Liquid formulation | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407424TA (en) | Methods for determining information about a communication parameter and communication devices | |
SG11201408646VA (en) | Dimeric protein with triple mutations | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201406625XA (en) | Anti-fcrn antibodies | |
SG11201408375RA (en) | Transfers in multiple-deck elevator systems | |
SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |